Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation (original) (raw)
Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System
Markus Muellner
Molecules
View PDFchevron_right
Group-based optimization of potent and cell-active inhibitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase: structure-activity relationships leading to the chemical probe (2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrr...
Ola Epemolu
Journal of medicinal chemistry, 2017
View PDFchevron_right
Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
Inge Van Molle, Alessio Ciulli
Journal of the American Chemical Society, 2012
View PDFchevron_right
The E3 ubiquitin ligase UBE3C enhances proteasome processivity by ubiquitinating partially proteolyzed substrates
Kyle Kovary
The Journal of biological chemistry, 2013
View PDFchevron_right
A Label-free Quantitative Proteomics Strategy to Identify E3 Ubiquitin Ligase Substrates Targeted to Proteasome Degradation
Sandrine UTTENWEILER
Molecular & Cellular Proteomics, 2009
View PDFchevron_right
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology
Sébastien Tardy
CHIMIA, 2020
View PDFchevron_right
Ubiquibodies, Synthetic E3 Ubiquitin Ligases Endowed with Unnatural Substrate Specificity for Targeted Protein Silencing
Jeffrey Varner
Journal of Biological Chemistry, 2014
View PDFchevron_right
3-Fluoro-4-hydroxyprolines: Synthesis, conformational analysis and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation
Xavier Lucas
View PDFchevron_right
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications
Ryan Whatling
SLAS Discovery, 2021
View PDFchevron_right
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Marjeta Urh
ACS Chemical Biology
View PDFchevron_right
Targeted degradation via direct 26S proteasome recruitment
Aaron Wecksler
Nature Chemical Biology
View PDFchevron_right
Exploiting the Endogenous Ubiquitin Proteasome System in Targeted Cancer Treatment
Haya Lorberboum-galski
Cancers
View PDFchevron_right
Protein degradation induced by PROTAC molecules as an emerging drug discovery strategy
Mladen Koravović, Journal of the Serbian Chemical Society, Gordana Tasić
Journal of the Serbian Chemical Society, 2022
View PDFchevron_right
Targeted protein degradation mechanisms
Jesse Chen
Drug Discovery Today: Technologies, 2019
View PDFchevron_right
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
Ipek Birced
Journal of Medicinal Chemistry, 2014
View PDFchevron_right
Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase
Stephen Hinshaw
bioRxiv (Cold Spring Harbor Laboratory), 2022
View PDFchevron_right
Quantitative Chemical Proteomic Profiling of Ubiquitin Specific Proteases in Intact Cancer Cells
Charlotte Knights
ACS Chemical Biology
View PDFchevron_right
Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation
Hollie Swanson
ChemBioChem, 2010
View PDFchevron_right
Structural basis of PROTAC cooperative recognition for selective protein degradation
Alessio Ciulli
Nature chemical biology, 2017
View PDFchevron_right
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics
Jeffrey Simard
SLAS Discovery, 2021
View PDFchevron_right
Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies
Xavier Lucas, Alessio Ciulli
View PDFchevron_right
Inhibition of the ubiquitin-proteasome system by a bioactivatable compound
Mikael Altun
2021
View PDFchevron_right
Identification of Piperlongumine (PL) as a new E3 ligase ligand to induce targeted protein degradation
Amin Sobh
bioRxiv (Cold Spring Harbor Laboratory), 2022
View PDFchevron_right
Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins
le trinh
Scientific reports, 2015
View PDFchevron_right
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Matthew Jones
Biochemical Journal, 2010
View PDFchevron_right
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities
Sonia Melino
Oncotarget, 2014
View PDFchevron_right
Placing a Disrupted Degradation Motif at the C Terminus of Proteasome Substrates Attenuates Degradation without Impairing Ubiquitylation
Yuval Reiss
Journal of Biological Chemistry, 2013
View PDFchevron_right
Editorial: E3 Ubiquitin Ligases: From Structure to Physiology
Victor Bolanos-garcia
Frontiers in Physiology, 2020
View PDFchevron_right
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay
Kenichi Shimada, Rachid Skouta
Cancer discovery, 2011
View PDFchevron_right
Detection of ubiquitin–proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development
Mikael Altun
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
View PDFchevron_right
Diggin′ on U(biquitin): A Novel Method for the Identification of Physiological E3 Ubiquitin Ligase Substrates
O. Alzate
Cell Biochemistry and Biophysics, 2013
View PDFchevron_right